Currency in GBP
Last close As at 30/03/2023
GBP7.75
▲ 25.00 (3.33%)
Market capitalisation
GBP740m
Research: TMT
discoverIE has seen a strong bounce-back in trading after the worst of the COVID pandemic, with organic revenue growth of 18% y-o-y in FY22 and 14% versus FY20 (pre-COVID). The combination of organic growth and recent high-margin acquisitions generated underlying operating profit growth of 34% y-o-y with a margin approaching 11%. Organic order growth of 36% y-o-y has provided a strong order book entering FY23. With FY22 underlying EPS beating our forecasts, we upgrade FY23 and introduce FY24 estimates. We expect further M&A as discoverIE continues with its strategy to consolidate the fragmented electronics market.
discoverIE Group |
Strong growth despite market challenges |
FY22 results |
Tech hardware and equipment |
17 June 2022 |
Share price performance
Business description
Next events
Analyst
discoverIEdiscoverIE Group Group is a research client of Edison Investment Research Limited |
discoverIE has seen a strong bounce-back in trading after the worst of the COVID pandemic, with organic revenue growth of 18% y-o-y in FY22 and 14% versus FY20 (pre-COVID). The combination of organic growth and recent high-margin acquisitions generated underlying operating profit growth of 34% y-o-y with a margin approaching 11%. Organic order growth of 36% y-o-y has provided a strong order book entering FY23. With FY22 underlying EPS beating our forecasts, we upgrade FY23 and introduce FY24 estimates. We expect further M&A as discoverIE continues with its strategy to consolidate the fragmented electronics market.
Year end |
Revenue |
PBT* |
Dil. EPS* |
DPS |
P/E |
Yield |
03/21 |
302.8 |
27.2 |
22.4 |
10.15 |
30.5 |
1.5 |
03/22 |
379.2 |
37.6 |
29.4 |
10.80 |
23.3 |
1.6 |
03/23e |
400.4 |
39.7 |
30.1 |
11.20 |
22.7 |
1.6 |
03/24e |
412.4 |
41.3 |
31.2 |
11.50 |
21.9 |
1.7 |
Note: *PBT and EPS as per discoverIE’s underlying metric, excluding amortisation of acquired intangibles and exceptional items.
FY22: Strong recovery
discoverIE reported 25% revenue growth for FY22 (18% on an organic, constant exchange rate (CER) basis), underlying operating profit growth of 34% and an underlying profit margin of 10.9% (+0.7pp y-o-y). Underlying EPS of 29.4p was 31% higher year-on-year, 20% higher versus FY20 and was 5.2% ahead of our forecast. Tight working capital control resulted in year-end net debt of £30.2m, well below our £37.9m forecast, bringing gearing down to an eight-year low of 0.6x. We upgrade our FY23 underlying EPS forecast by 4.8% and introduce FY24 estimates.
Outlook: FY23 underpinned by order book
Organic order growth of 36% y-o-y (+32% versus FY20) resulted in a book-to-bill ratio of 1.19:1 in FY22 and a year-end order book worth £224m (c 6.5 months forward visibility). Management has navigated COVID disruption and supply chain issues well over the past two years and views the current inflationary and supply chain pressures as manageable. Strong organic sales growth continues year-to-date and we believe the focus on strategic growth markets should help the company to meet its target of exceeding GDP growth, even during periods of economic uncertainty.
Valuation: M&A to accelerate margin expansion
The stock now trades slightly above the average of its broader UK electronics peer group on a P/E basis for FY23 but is below industrial peers with a similar decentralised operating model (such as Halma and Spirax). The focus on strategic growth markets supports sustained organic revenue growth and we see potential for upside to earnings through operating margin expansion and accretive acquisitions. The company has headroom for further acquisitions, with gearing of 0.6x well below the target range of 1.5–2.0x, a recently expanded credit facility and a strong pipeline of opportunities.
Review of FY22 results
Exhibit 1: FY22 results versus forecasts and FY21
£m |
FY21a |
FY22e |
FY22a |
Diff |
y-o-y |
Revenues |
302.8 |
377.7 |
379.2 |
0.4% |
25.2% |
EBITDA |
44.0 |
55.4 |
56.1 |
1.3% |
27.5% |
EBITDA margin |
14.5% |
14.7% |
14.8% |
0.1% |
0.3% |
Underlying operating profit |
30.8 |
40.5 |
41.4 |
2.3% |
34.4% |
Underlying operating margin |
10.2% |
10.7% |
10.9% |
0.2% |
0.7% |
Normalised operating profit |
31.9 |
42.9 |
44.8 |
4.5% |
40.4% |
Normalised operating margin |
10.5% |
11.3% |
11.8% |
0.5% |
1.3% |
Underlying PBT |
27.2 |
36.3 |
37.6 |
3.6% |
38.2% |
Normalised PBT |
28.3 |
38.7 |
41.0 |
5.9% |
44.9% |
Normalised net income |
21.6 |
28.6 |
30.8 |
7.4% |
42.4% |
Normalised diluted EPS (p) |
23.4 |
29.8 |
32.1 |
7.6% |
37.1% |
Underlying diluted EPS (p) |
22.4 |
28.0 |
29.4 |
5.2% |
31.1% |
Reported basic EPS (p) |
13.5 |
17.2 |
27.1 |
57.3% |
100.4% |
Dividend per share (p) |
10.2 |
10.8 |
10.8 |
0.5% |
6.4% |
Net (debt)/cash |
(47.2) |
(37.9) |
(30.2) |
(20.2%) |
(36.0%) |
Net debt/EBITDA (x) |
1.1 |
0.7 |
0.6 |
Source: discoverIE, Edison Investment Research
We upgraded our forecasts in April when discoverIE provided its year-end trading update. Results were ahead of our upgraded estimates, with underlying diluted EPS 5.2% ahead of our forecast and 4.4% ahead of consensus. Underlying operating profit was 2.2% ahead of our forecast, with net finance costs £0.4m below our forecast and the effective tax rate of 25.0% 1pp lower than our forecast. Reported EPS includes one-off charges of £6.5m relating to acquisitions, £14m amortisation of acquired intangibles, £3.4m in share-based payments and a £15.5m contribution from discontinued operations (£9.3m results for the year plus £6.2m gain on sale).
The company declared a final dividend of 7.45p per share to make a full year dividend of 10.8p, 0.05p ahead of our forecast.
During FY22, the company disposed of its Custom Supply business for £45m (with a further £5m deferred for three years), raised £55m (gross) from an equity issue, and spent £85m on three high margin acquisitions: Beacon, Antenova and CPI, all with 20%+ operating margins. Tight control of working capital resulted in net debt well below our estimate at year-end and gearing of 0.6x versus the 0.7x disclosed in the April trading update.
Order intake increased 36% y-o-y on an organic basis and 32% versus FY20. The order book at the end of FY22 stood at £224m, up 62% y-o-y on an organic basis and 71% versus end FY20.
New divisional presentation
This is the first full year of reporting for the company since Custom Supply was sold and the remaining Design & Manufacturing business was organised into two divisions: Magnetics & Controls and Sensing & Connectivity. Exhibit 2 summarises divisional revenue, order and operating profit performance.
Exhibit 2: Divisional performance
£m |
FY22 |
FY21 |
Reported y-o-y |
CER y-o-y |
Organic CER y-o-y |
Organic order growth y-o-y |
Revenues |
||||||
Magnetics & Controls |
234.7 |
190.4 |
23% |
27% |
22% |
36% |
Sensing & Connectivity |
144.5 |
112.4 |
29% |
31% |
11% |
36% |
Total revenues |
379.2 |
302.8 |
25% |
28% |
18% |
36% |
Underlying operating profit |
||||||
Magnetics & Controls |
29.8 |
23.4 |
27% |
|||
Sensing & Connectivity |
23.3 |
15.5 |
50% |
|||
Unallocated |
(11.7) |
(8.1) |
44% |
|||
Total operating profit |
41.4 |
30.8 |
34% |
|||
Underlying operating margin |
||||||
Magnetics & Controls |
12.7% |
12.3% |
0.4% |
|||
Sensing & Connectivity |
16.1% |
13.8% |
2.3% |
|||
Total operating margin |
10.9% |
10.2% |
0.7% |
Source: discoverIE
Magnetics & Controls
This business saw reported revenue growth of 23% in FY22, or 27% on a CER basis. Organic constant currency growth was 22%. This division includes the Beacon business acquired in H122 as well as eight businesses operating in 16 countries. Two businesses in this division were affected by the shortage of semiconductor components, slightly reducing the gross margin, but despite this, underlying operating profit grew 27% y-o-y and the margin expanded by 0.4pp.
Orders increased 36% y-o-y on an organic basis to £280m with a book-to-bill ratio of 1.19:1 in FY22.
This division has 20 manufacturing facilities and during the year production began at a new, larger facility in Mexico. Capacity at facilities in the US and India is being expanded.
Sensing & Connectivity
This division includes the Antenova and CPI acquisitions that were made in H122 as well as 12 businesses operating in nine countries. Revenue grew 29% y-o-y on a reported basis, 31% at CER and 11% on an organic basis. Geographically, Europe saw 13% organic growth and Asia 6%, while the slower recovery of some transport infrastructure projects along with semiconductor shortages resulted in flat revenues in North America. Underlying operating profit increased 50% y-o-y and the margin expanded 2.3pp, helped by the higher margin acquisitions in H122.
Orders increased 36% y-o-y on an organic basis to £173m with a book-to-bill ratio of 1.20:1.
In both divisions, management has noted a trend for customers to localise production – in particular, it has seen volumes shift from China to India. This has an environmental benefit as product has shorter distances to travel to reach customers, and reduces an element of geopolitical risk.
Update on ESG strategy
When we wrote in December, we outlined the company’s ESG strategy and targets (Record order book drives upgrades). Since then, the company has been awarded an ‘A’ rating by MSCI.
As this is the first year that the UK requirement for Task Force on Climate-Related Financial Disclosures reporting is in force, the company has undertaken a preliminary assessment of the resilience of its business model and strategy and the potential effects of climate change over the short and medium term. It has concluded that while it is exposed to certain risks during the transition to a low carbon economy, such risks are considered to be low and are outweighed by opportunities presented to the company.
Since the disposal of the Custom Supply business, the target to reduce carbon emissions by 50% by 2025 (start point end CY19) has been rebased to reflect the remaining business (excluding acquisitions for the first 12 months). The strategy to achieve net zero is still being determined. As at the end of CY21, carbon emissions had been reduced by 33% compared to 6% at the end of CY20, mainly through switching to renewable sources of energy at manufacturing sites.
In 2020 the company set a target for 80% of operations, by revenue, to be covered by an ISO 14001 accreditation by the end of 2025. At the end of CY21, 63% of operations had achieved this accreditation.
Well financed for further M&A
After making three acquisitions in H122, the company paused for breath. With the decline in equity markets, we believe that pricing in private markets is likely to follow suit, which could provide opportunities for discoverIE.
In May, the company increased its syndicated banking facility from £180m to £240m and extended the term of the facility by two years to June 2026. It has an option to extend this to June 2027 as well as an £80m accordion facility. Gearing of 0.6x at the end of FY22 was well below the target range of 1.5–2.0x providing plenty of headroom for further deals.
Update on targets
The company regularly updates on its target key strategic indicators (KSIs) and key performance indicators (KPIs) – see Exhibit 3. With the FY21 performance affected by the COVID pandemic, the company has treated FY21 and FY22 as a composite period to show the real underlying performance. The table shows performance including Custom Supply up to and including FY20.
discoverIE is making good progress towards its FY25 targets. Looking at the KSIs, the company expects to meet the operating margin target through a combination of organic growth and acquisitions of higher-margin businesses (targeting companies with a minimum 15% operating margin). Sales from target markets reached 76% of the total and made up 86% of design wins during FY22.
Looking at the KPIs, group organic revenue of 14% compared to FY20 (18% versus FY21) was well ahead of GDP growth over the same period (9% from March 2020 to March 2022). The company has achieved a compound annual growth rate (CAGR) of 10% for organic revenue from FY18–22. Underlying EPS grew 20% compared to FY20 and has grown at a CAGR of 26% FY18–22. While ROCE slipped just below the 15% target, the company noted that acquisitions often start below the target but as they are integrated, move above it. Operating profit and free cash flow conversion both exceeded 100% compared with their 85% targets averaged over a two year-period (as disclosed in Exhibit 3). On a one-year basis, operating profit conversion was 141% in FY21 and 80% in FY22, reflecting working capital flows as revenue declined during the pandemic and then recovered in FY22. Free cash flow conversion was 157% in FY21 and 77% in FY22, for similar reasons.
Exhibit 3: Key strategic and performance indicators |
Source: discoverIE ROCE: return on capital employed |
Outlook and changes to forecasts
Management noted that FY23 has started well, with continued strong growth in organic sales and the order book at record high levels. While supply chain headwinds and inflationary pressures remain, the company views these as manageable.
The company has generally been able to pass on increased input costs to customers, although this may not always be the case if cost increases show no sign of abating. Management noted that pricing for some raw materials has started to stabilise, and it is seeing better availability of some semiconductor components. In-house manufacturing tends to use a relatively low level of bought-in components, which reduces the company’s exposure to supply chain shortages. Labour costs are increasing at double-digit rates in lower cost regions and at c 4–5% in higher cost regions, with bonus schemes helping to dampen demand for increases.
The strong order book at the end of FY22 provides the company with c 6.5 months of revenue visibility, up from the low of c 2.5 months during the pandemic and a pre-COVID level of 4–4.5 months. Customers have been placing both higher volumes of orders and ordering further ahead to be sure of availability. While it is possible that some customers may reduce their own inventory as supply chain issues abate, any slowdown in order intake is likely to be due to reverting to shorter order windows. Management believes it is likely that growth of the order book will moderate and revert to pre-COVID levels (in terms of months of revenue), although it has seen no signs of this happening yet.
We have revised our forecasts to reflect the better-than-expected outturn in FY22. We raise our revenue estimate by 1% in FY23 and our underlying EPS estimate by 4.8%. For FY24, we conservatively forecast revenue growth of 3% and underlying EPS growth of 3.6%.
Exhibit 4: Changes to forecasts
£m |
FY23e old |
FY23e new |
Change |
y-o-y |
FY24e new |
y-o-y |
Revenues |
396.4 |
400.4 |
1.0% |
5.6% |
412.4 |
3.0% |
EBITDA |
58.2 |
58.7 |
0.9% |
4.7% |
60.2 |
2.5% |
EBITDA margin |
14.7% |
14.7% |
(0.0%) |
(0.1%) |
14.6% |
(0.1%) |
Underlying operating profit |
42.7 |
43.7 |
2.3% |
5.7% |
45.0 |
2.8% |
Underlying operating margin |
10.8% |
10.9% |
0.1% |
0.0% |
10.9% |
(0.0%) |
Normalised operating profit |
45.1 |
46.1 |
2.2% |
3.0% |
47.4 |
2.7% |
Normalised operating margin |
11.4% |
11.5% |
0.1% |
(0.3%) |
11.5% |
(0.0%) |
Underlying PBT |
38.4 |
39.7 |
3.4% |
5.5% |
41.3 |
4.1% |
Normalised PBT |
40.8 |
42.1 |
3.2% |
2.6% |
43.7 |
3.9% |
Normalised net income |
30.0 |
31.4 |
4.6% |
2.0% |
32.6 |
3.9% |
Normalised diluted EPS (p) |
30.5 |
32.0 |
4.6% |
(0.5%) |
33.0 |
3.4% |
Underlying diluted EPS (p) |
28.8 |
30.1 |
4.8% |
2.4% |
31.2 |
3.6% |
Reported basic EPS (p) |
14.6 |
15.7 |
7.3% |
(42.0%) |
16.9 |
7.6% |
Dividend per share (p) |
11.2 |
11.2 |
0.0% |
3.2% |
11.5 |
3.1% |
Net (debt)/cash |
(31.6) |
(32.9) |
3.9% |
8.9% |
(22.9) |
(30.5%) |
Net debt/EBITDA (x) |
0.6 |
0.6 |
0.4 |
Source: Edison Investment Research
Valuation
The share price is down 33% year-to-date, slightly more than the average for the peer group of 28%. It now trades marginally above the average of its broader UK electronics peer group on a P/E basis for FY23 but is below industrial peers with a similar decentralised operating model (such as Halma and Spirax). The focus on strategic growth markets supports sustained organic revenue growth and we see potential for upside to earnings through operating margin expansion and accretive acquisitions. The company has headroom for further acquisitions, with gearing of 0.6x well below the target range of 1.5–2.0x, a recently expanded credit facility and a strong pipeline of opportunities.
Exhibit 5: Peer valuation multiples
EV/sales (x) |
EV/EBITDA (x) |
EV/EBIT (x) |
P/E (x) |
Div yield (%) |
||||||
CY |
NY |
CY |
NY |
CY |
NY |
CY |
NY |
CY |
NY |
|
DiscoverIE |
1.7 |
1.7 |
11.6 |
11.4 |
14.8 |
14.4 |
22.7 |
21.9 |
1.6 |
1.7 |
Diploma |
3.3 |
3.0 |
15.3 |
14.2 |
18.6 |
17.1 |
22.0 |
20.5 |
2.2 |
2.3 |
Gooch & Housego |
1.8 |
1.6 |
11.7 |
9.6 |
20.3 |
15.3 |
24.1 |
18.4 |
1.4 |
1.5 |
TT electronics |
0.9 |
0.8 |
7.8 |
6.7 |
10.6 |
8.8 |
11.3 |
9.4 |
3.3 |
3.8 |
XP Power |
2.4 |
2.3 |
10.1 |
9.1 |
12.9 |
11.2 |
15.4 |
13.9 |
3.1 |
3.3 |
Avon Protection |
1.6 |
1.5 |
11.5 |
7.4 |
18.8 |
11.4 |
22.5 |
12.3 |
3.9 |
4.3 |
Halma |
4.8 |
4.5 |
18.8 |
17.6 |
22.3 |
20.8 |
28.0 |
26.2 |
1.0 |
1.1 |
Spectris |
2.3 |
2.2 |
11.4 |
10.7 |
13.5 |
12.8 |
18.3 |
16.7 |
2.6 |
2.8 |
Spirax-Sarco Engineering |
4.8 |
4.5 |
17.2 |
16.0 |
19.9 |
18.6 |
26.9 |
25.2 |
1.5 |
1.6 |
Average |
2.7 |
2.5 |
13.0 |
11.4 |
17.1 |
14.5 |
21.1 |
17.8 |
2.4 |
2.6 |
Premium/(discount) to average |
(37.4) |
(34.9) |
(10.2) |
(0.4) |
(13.4) |
(0.3) |
7.9 |
23.2 |
(32.3) |
(35.6) |
Source: Edison Investment Research, Refinitiv. Note: Priced at 16 June 2022.
Exhibit 6: Financial summary
£m |
2020 |
2021 |
2022 |
2023e |
2024e |
||
Year end 31 March |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|||||||
Revenue |
|
|
297.9 |
302.8 |
379.2 |
400.4 |
412.4 |
EBITDA |
|
|
43.6 |
44.0 |
56.1 |
58.7 |
60.2 |
Normalised operating Profit (before am, SBP and except.) |
31.6 |
31.9 |
44.8 |
46.1 |
47.4 |
||
Underlying operating Profit (before am. and except.) |
29.8 |
30.8 |
41.4 |
43.7 |
45.0 |
||
Amortisation of acquired intangibles |
(9.0) |
(11.1) |
(14.0) |
(16.5) |
(16.5) |
||
Exceptionals |
(4.3) |
(2.6) |
(6.5) |
(3.0) |
(3.0) |
||
Share-based payments |
(1.8) |
(1.1) |
(3.4) |
(2.4) |
(2.4) |
||
Operating Profit |
16.5 |
17.1 |
20.9 |
24.2 |
25.5 |
||
Net Interest |
(4.3) |
(3.6) |
(3.8) |
(4.1) |
(3.7) |
||
Profit Before Tax (norm) |
|
|
27.3 |
28.3 |
41.0 |
42.1 |
43.7 |
Profit Before Tax (FRS 3) |
|
|
12.2 |
13.5 |
17.1 |
20.2 |
21.8 |
Tax |
(3.3) |
(4.0) |
(7.4) |
(5.1) |
(5.5) |
||
Profit After Tax (norm) |
21.8 |
21.6 |
30.8 |
31.4 |
32.6 |
||
Profit After Tax (FRS 3) |
8.9 |
9.5 |
9.7 |
15.0 |
16.3 |
||
Discontinued operations |
5.4 |
2.5 |
15.5 |
0.0 |
0.0 |
||
Net income (norm) |
21.8 |
21.6 |
30.8 |
31.4 |
32.6 |
||
Net income (FRS 3) |
14.3 |
12.0 |
25.2 |
15.0 |
16.3 |
||
Ave. Number of Shares Outstanding (m) |
84.0 |
88.8 |
93.0 |
95.7 |
96.2 |
||
EPS - normalised & diluted (p) |
|
|
25.1 |
23.4 |
32.1 |
32.0 |
33.0 |
EPS - underlying, diluted (p) |
|
|
24.4 |
22.4 |
29.4 |
30.1 |
31.2 |
EPS - IFRS basic (p) |
|
|
17.0 |
13.5 |
27.1 |
15.7 |
16.9 |
EPS - IFRS diluted (p) |
|
|
16.5 |
13.0 |
26.3 |
15.3 |
16.5 |
Dividend per share (p) |
3.0 |
10.2 |
10.8 |
11.2 |
11.5 |
||
EBITDA Margin (%) |
14.6 |
14.5 |
14.8 |
14.7 |
14.6 |
||
Normalised operating margin (before am, SBP and except.) (%) |
10.6 |
10.5 |
11.8 |
11.5 |
11.5 |
||
discoverIE underlying operating margin (%) |
10.0 |
10.2 |
10.9 |
10.9 |
10.9 |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
236.4 |
244.6 |
326.5 |
318.9 |
307.1 |
Intangible Assets |
182.2 |
190.8 |
263.3 |
252.8 |
238.3 |
||
Tangible Assets |
46.3 |
45.9 |
45.4 |
48.3 |
51.0 |
||
Deferred tax assets |
7.9 |
7.9 |
17.8 |
17.8 |
17.8 |
||
Current Assets |
|
|
197.4 |
183.6 |
196.8 |
204.5 |
214.6 |
Stocks |
68.4 |
67.7 |
77.8 |
85.6 |
88.1 |
||
Debtors |
90.1 |
84.9 |
78.0 |
85.6 |
88.1 |
||
Cash |
36.8 |
29.2 |
39.4 |
31.7 |
36.7 |
||
Current Liabilities |
|
|
(103.6) |
(107.8) |
(120.9) |
(126.9) |
(130.2) |
Creditors |
(94.0) |
(102.2) |
(114.2) |
(120.2) |
(123.5) |
||
Lease liabilities |
(5.3) |
(4.8) |
(4.7) |
(4.7) |
(4.7) |
||
Short term borrowings |
(4.3) |
(0.8) |
(2.0) |
(2.0) |
(2.0) |
||
Long Term Liabilities |
|
|
(129.7) |
(112.0) |
(112.0) |
(100.7) |
(89.5) |
Long term borrowings |
(93.8) |
(75.6) |
(67.6) |
(62.6) |
(57.6) |
||
Lease liabilities |
(14.7) |
(16.7) |
(16.4) |
(15.7) |
(15.0) |
||
Other long term liabilities |
(21.2) |
(19.7) |
(28.0) |
(22.4) |
(16.9) |
||
Net Assets |
|
|
200.5 |
208.4 |
290.4 |
295.8 |
302.0 |
CASH FLOW |
|||||||
Operating Cash Flow |
|
|
48.0 |
56.8 |
42.5 |
44.3 |
53.3 |
Net Interest |
(3.7) |
(3.1) |
(3.3) |
(3.6) |
(3.2) |
||
Tax |
(6.4) |
(7.2) |
(7.1) |
(10.7) |
(11.1) |
||
Capex |
(6.3) |
(3.9) |
(6.2) |
(9.0) |
(9.0) |
||
Acquisitions/disposals |
(73.6) |
(20.5) |
(46.8) |
(6.0) |
(2.0) |
||
Financing |
53.9 |
(6.6) |
46.1 |
(7.2) |
(7.2) |
||
Dividends |
(8.1) |
(2.8) |
(9.4) |
(10.4) |
(10.9) |
||
Net Cash Flow |
3.8 |
12.7 |
15.8 |
(2.5) |
10.0 |
||
Opening net cash/(debt) |
|
|
(63.3) |
(61.3) |
(47.2) |
(30.3) |
(32.9) |
HP finance leases initiated |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Other |
(1.8) |
1.4 |
1.1 |
0.0 |
0.0 |
||
Closing net cash/(debt) |
|
|
(61.3) |
(47.2) |
(30.3) |
(32.9) |
(22.9) |
Source: discoverIE, Edison Investment Research
|
|
Research: Healthcare
InMed Pharmaceuticals has announced the launch of tetrahydrocannabivarin (d9-THCV) into B2B sales for the health and wellness industry. This marks the latest addition to its growing commercial footprint in high-value rare cannabinoids. Unlike tetrahydrocannabinol (THC), THCV is non-psychoactive and has shown indications of potential activity in combating obesity, diabetes, anxiety, Alzheimer’s disease and epilepsy. The launch and commercialization will be supported by InMed’s recently announced private placement, raising gross proceeds of $5m, potentially extending its cash runway into CY23. We adjust our valuation to account for the recent share offering and cash received to $85m (base, $4.1/share) versus our prior $80m (base, $5.6/share).
Get access to the very latest content matched to your personal investment style.